Treatment Outcomes of Fluoroquinolone- Resistant Multidrug-Resistant Tuberculosis: An Implication for Delamanid - Authors' Reply.
作者信息
Kim Saerom, Mok Jeongha
机构信息
Department of Internal Medicine, Pusan National University Hospital, Busan, Republic of Korea.
Biomedical Research Institute, Pusan National University Hospital, Busan, Republic of Korea.
出版信息
Tuberc Respir Dis (Seoul). 2024 Apr;87(2):209-211. doi: 10.4046/trd.2024.0010. Epub 2024 Jan 30.
Abstract
摘要
相似文献
1
Treatment Outcomes of Fluoroquinolone- Resistant Multidrug-Resistant Tuberculosis: An Implication for Delamanid - Authors' Reply.耐氟喹诺酮类多重耐药结核病的治疗结果：对地拉曼的启示——作者回复
Tuberc Respir Dis (Seoul). 2024 Apr;87(2):209-211. doi: 10.4046/trd.2024.0010. Epub 2024 Jan 30.
2
9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea.9 个月的德拉马尼德、利奈唑胺、左氧氟沙星和吡嗪酰胺与常规疗法治疗氟喹诺酮敏感的耐多药结核病（MDR-END）：韩国多中心、随机、开放标签 2/3 期非劣效性试验。
Lancet. 2022 Oct 29;400(10362):1522-1530. doi: 10.1016/S0140-6736(22)01883-9.
3
Treatment Outcomes of Fluoroquinolone-Resistant Multidrug-Resistant Tuberculosis: An Implication for Delamanid.耐氟喹诺酮多药耐药结核病的治疗结果：对地拉曼的启示
Tuberc Respir Dis (Seoul). 2024 Apr;87(2):206-208. doi: 10.4046/trd.2023.0188. Epub 2023 Dec 18.
4
Outcomes of Multidrug-Resistant Tuberculosis Treated With Bedaquiline or Delamanid.贝达喹啉或德拉马尼治疗耐多药结核病的结果。
Clin Infect Dis. 2021 Oct 20;73(8):1362-1369. doi: 10.1093/cid/ciab304.
5
Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.地拉米胺、利奈唑胺、左氧氟沙星和吡嗪酰胺用于治疗氟喹诺酮敏感的耐多药结核病患者（使用现有和新药缩短耐多药结核病治疗时间，MDR-END）：一项II/III期、多中心、随机、开放标签临床试验的研究方案
Trials. 2019 Jan 16;20(1):57. doi: 10.1186/s13063-018-3053-1.
6
QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial.贝达喹啉、德拉马尼或两者联合治疗利福平耐药结核病患者的 QT 影响：一项 2 期、开放标签、随机、对照试验。
Lancet Infect Dis. 2021 Jul;21(7):975-983. doi: 10.1016/S1473-3099(20)30770-2. Epub 2021 Feb 12.
7
Clinical Outcomes Among Patients With Drug-resistant Tuberculosis Receiving Bedaquiline- or Delamanid-Containing Regimens.接受贝达喹啉或德拉马尼包含方案治疗的耐药结核病患者的临床结局。
Clin Infect Dis. 2020 Dec 3;71(9):2336-2344. doi: 10.1093/cid/ciz1107.
8
Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial.德拉马尼联合优化背景治疗方案治疗耐多药结核病的疗效和安全性：一项多中心、随机、双盲、安慰剂对照、平行分组 3 期临床试验。
Lancet Respir Med. 2019 Mar;7(3):249-259. doi: 10.1016/S2213-2600(18)30426-0. Epub 2019 Jan 7.
9
Delamanid for multidrug-resistant pulmonary tuberculosis.德拉马尼治疗耐多药肺结核。
N Engl J Med. 2012 Jun 7;366(23):2151-60. doi: 10.1056/NEJMoa1112433.
10
Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.在德国，将新型或第5组干预措施添加到背景治疗方案中用于治疗耐多药结核病的成本效益。
BMC Health Serv Res. 2017 Mar 8;17(1):182. doi: 10.1186/s12913-017-2118-2.
本文引用的文献
1
Impact of Anti-Tuberculosis Drug Use on Treatment Outcomes in Patients with Pulmonary Fluoroquinolone-Resistant Multidrug-Resistant Tuberculosis: A Nationwide Retrospective Cohort Study with Propensity Score Matching.抗结核药物使用对耐氟喹诺酮类多药耐药肺结核患者治疗结局的影响：一项采用倾向评分匹配的全国性回顾性队列研究
Tuberc Respir Dis (Seoul). 2023 Jul;86(3):234-244. doi: 10.4046/trd.2023.0040. Epub 2023 May 31.
2
9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea.9 个月的德拉马尼德、利奈唑胺、左氧氟沙星和吡嗪酰胺与常规疗法治疗氟喹诺酮敏感的耐多药结核病（MDR-END）：韩国多中心、随机、开放标签 2/3 期非劣效性试验。
Lancet. 2022 Oct 29;400(10362):1522-1530. doi: 10.1016/S0140-6736(22)01883-9.
3
Bedaquiline, Delamanid, Linezolid and Clofazimine for Treatment of Pre-extensively Drug-Resistant Tuberculosis.贝达喹啉、地拉曼尼、利奈唑胺和氯法齐明用于治疗广泛耐药前结核病
Clin Infect Dis. 2022 Jun 29;76(3):e938-46. doi: 10.1093/cid/ciac528.
4
Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs.来自 14 个国家队列的耐多药结核病患者同时接受贝达喹啉、德拉马尼和其他二线药物治疗的安全性和有效性结果。
Clin Infect Dis. 2022 Oct 12;75(8):1307-1314. doi: 10.1093/cid/ciac176.
5
Outcomes of Multidrug-Resistant Tuberculosis Treated With Bedaquiline or Delamanid.贝达喹啉或德拉马尼治疗耐多药结核病的结果。
Clin Infect Dis. 2021 Oct 20;73(8):1362-1369. doi: 10.1093/cid/ciab304.
6
Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.地拉米胺、利奈唑胺、左氧氟沙星和吡嗪酰胺用于治疗氟喹诺酮敏感的耐多药结核病患者（使用现有和新药缩短耐多药结核病治疗时间，MDR-END）：一项II/III期、多中心、随机、开放标签临床试验的研究方案
Trials. 2019 Jan 16;20(1):57. doi: 10.1186/s13063-018-3053-1.
7
Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial.德拉马尼联合优化背景治疗方案治疗耐多药结核病的疗效和安全性：一项多中心、随机、双盲、安慰剂对照、平行分组 3 期临床试验。
Lancet Respir Med. 2019 Mar;7(3):249-259. doi: 10.1016/S2213-2600(18)30426-0. Epub 2019 Jan 7.
8
Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.肺耐多药结核病成功治疗结果的相关因素：一项个体患者数据荟萃分析。
Lancet. 2018 Sep 8;392(10150):821-834. doi: 10.1016/S0140-6736(18)31644-1.
9
Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa.德拉马尼治疗利福平耐药结核病：来自南非的回顾性研究。
Eur Respir J. 2018 Jun 14;51(6). doi: 10.1183/13993003.00017-2018. Print 2018 Jun.
10
Principles for constructing a tuberculosis treatment regimen: the role and definition of core and companion drugs.构建结核病治疗方案的原则：核心药物和辅助药物的作用和定义。
Int J Tuberc Lung Dis. 2018 Mar 1;22(3):239-245. doi: 10.5588/ijtld.17.0660.
Zotero 插件